The design of a component to elicit broadly neutralizing antibodies is thought to be crucial for a successful HIV vaccine but is proving very difficult. In particular, immunogens designed from study of broadly neutralizing human monoclonal antibodies have generally failed to elicit antibodies with the appropriate specificities. A number of hypotheses have been advanced for these failures including restricted access to broadly neutralizing epitopes in recessed sites on the virus surface, proximity of the epitopes to viral membranes and epitope mimicry of self-antigens. In this new R01 proposal, we propose to generate transgenic mice carrying genes encoding two of the broadly neutralizing HIV antibodies 4E10 and b12 to investigate these hypotheses and to provide tools to study and rank potential HIV vaccine candidates. In the first instance, we propose to use mice carrying HIV antibody genes targeted to the physiological Ig loci to test if 4E10 and b12 have biologically relevant self-reactivity. If self-reactive, the B cells generated in 4E10 and b12 transgenic mice will be regulated by the immune tolerance mechanisms of receptor editing, anergy induction, or deletion and these mechanisms will be dissected. This may allow the design of immunogens in the future that do not evoke self-responses. If non-tolerant, transgenic mice carrying the 4E10 or b12 specificities should carry a greatly increased precursor frequency of B cells that are broadly neutralizing for HIV. We will then use an array of immunogens to explore the origins of any restrictions on eliciting 4E10 and b12 antibody specificities, to evaluate the most promising immunogens and ultimately to guide the design of modified and new immunogens to elicit broadly neutralizing antibodies. Relevance: To be successful, it is likely that an HIV vaccine must stimulate neutralizing antibodies. This proposal provides a mouse model to understand some of the problems in stimulating such antibodies by various vaccine candidates and to thereby suggest how better candidates can be designed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI073148-05
Application #
8039277
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Pullen, Jeffrey K
Project Start
2007-04-15
Project End
2013-03-31
Budget Start
2011-04-01
Budget End
2013-03-31
Support Year
5
Fiscal Year
2011
Total Cost
$455,501
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Nemazee, David (2017) Mechanisms of central tolerance for B cells. Nat Rev Immunol 17:281-294
Medina-Ramírez, Max; Garces, Fernando; Escolano, Amelia et al. (2017) Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med 214:2573-2590
Ingale, Jidnyasa; Stano, Armando; Guenaga, Javier et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15:1986-99
Briney, Bryan; Sok, Devin; Jardine, Joseph G et al. (2016) Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166:1459-1470.e11
He, Linling; de Val, Natalia; Morris, Charles D et al. (2016) Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun 7:12041
Jardine, Joseph G; Ota, Takayuki; Sok, Devin et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61
Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-6
Doores, Katie J; Huber, Michael; Le, Khoa M et al. (2013) 2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. J Virol 87:2234-41
Ota, Takayuki; Doyle-Cooper, Colleen; Cooper, Anthony B et al. (2013) B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol 191:3179-85
Doyle-Cooper, Colleen; Hudson, Krystalyn E; Cooper, Anthony B et al. (2013) Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol 191:3186-3191

Showing the most recent 10 out of 12 publications